

Executive Report 2025

Executive Report 2025



1. PRESENTATION

The Hospital Clínico Universitario of Valencia Research Foundation was established in the year 2000 as the first Valencian research foundation affiliated with a public hospital. Ten years later, various centres of excellence in biomedical research from the University of Valencia and Carlos Simón Foundation signed specific agreements to join the foundation, and thus INCLIVA Biomedical Research Institute was formed.

INCLIVA's main aims are to manage the biomedical research carried out by the Hospital Clínico Universitario de Valencia and its Health Department, and to encourage teaching and scientific activities, thus improving patient treatment and knowledge sharing.

In 2011 INCLIVA was accredited as a Biomedical Research Institute by the Ministry of Science and Innovation (Ministerio de Ciencia e Innovación), thus obtaining preferential treatment from the Carlos III Health Institute (Instituto de Salud Carlos III) in recognition of its excellence in research.

INCLIVA's accreditation as Health Research Institute was officially renewed for five years in 2021.

2. STRUCTURE OF INCLIVA

INCLIVA Biomedical Research Institute (INCLIVA) conducts research in five R&I areas organized into 41 research groups, including nine emerging and nine associated clinical groups. All the groups develop their scientific activity with a common goal: to respond to healthcare needs and improve the R&D&i system.



Mission

Offer solutions to public health issues via scientific activity of the highest quality applied to healthcare.

Vision

Establish our institute as a centre of scientific excellence by developing research that maximizes existing resources and capabilities, increasing quality and societal impact.

Values

Citizen-oriented and committed to society: to find solutions to society's main health challenges while committing to transparency, respect for the environment and sustainability.

Excellence: a permanent focus on scientific and management excellence.


Support for professionals: equal opportunities, attracting young talent and retaining established talent.

Transparency: all work carried out at every level must be transmitted to all the institution's professionals, who must be aware of the processes, decisions and results obtained.

Partnerships and collaboration: successful scientific activity depends on strengthening collaborative ties, both internally and externally, to improve the quality and impact of the results.

Transversal scientific programmes

In line with its commitment to promoting collaborative and multidisciplinary research, INCLIVA has established a structure organized around seven scientific programmes focused on specific diseases from a translational perspective:



During 2025, INCLIVA worked on updating its Cooperative Scientific Project, creating the following new cross-cutting programmes approved in December 2025 and active since 2026:



CARDIOVASCULAR
AREA

Coordinator:
Francisco Javier Chorro Gascó

Mission: to contribute to the understanding of different aspects of cardiovascular disease (CVD) from its origins to its consequences.

13 research groups

- Research Group on Cardiometabolic Risk and Diabetes
José Tomás Real Collado
Sergio Martínez Hervás
- Genomics and Diabetes Unit
Felipe Javier Chaves Martínez
- Research Group on Cardiac Experimental Electrophysiology
Francisco Javier Chorro Gascó
Antonio M. Alberola Aguilar
- Research Group on Endothelial Cells (LINCE)
Susana Novella del Campo
Carlos Hermenegildo Caudevilla
- Research Group on Clinical Cardiology
Juan Sanchis Forés
- Research Group for the Prevention of Cardiovascular Risk in Children and Adolescents
Empar Lurbe i Ferrer

- Cardiometabolic Research Group on Primary Care
Jorge Navarro Pérez
- Research Group on the Study of Cardiometabolic and Renal Risk
Josep Redón i Mas
Raquel Cortés Vergaz
- Research Group on Vascular Function
José María Vila Salinas
María Dolores Mauricio Aviñó
- Research Group on Paediatric Nutrition
Cecilia Martínez Costa
- Group on Translational Research in Ischemic Heart Disease
Vicente Bodí Peris
- Research Group on Heart Failure
Julio Núñez Villota
- Research Group on Renal Disease
Jose Luis Górriz Teruel

Number of publications

195

Average IF

10.8

Number of research projects

65

Since December 2025, the coordination of this area has been renewed, and the following new coordinators appointed:



Coordinator:
Sergio Martínez Hervás



Coordinator:
Julio Núñez Villota



ONCOLOGY AREA

Coordinator:

Andrés Cervantes Ruipérez

Mission: advance understanding of different aspects of oncological diseases, at the stage of diagnosis and molecular characterization and selection of specific molecular targets of therapeutic interest.

12 research groups:

- Research Group on Histopathology and Tissue Engineering
Manuel Mata Roig
- Research Group on Innovative Diagnostic and Therapeutical Developments in Solid Tumours – InDeST
Andrés Cervantes Ruipérez
- Research Group on Breast Cancer Biology
Ana Lluch Hernández
Pilar Eroles Asensio
- Research Group on Skin Cancer
José Carlos Monteagudo Castro
- Translational Research Group on Paediatric Solid Tumours
Samuel Navarro Fos
Rosa Noguera Salvá

- Research Group on Hematopoietic Transplantation
Carlos Solano Vercet
- Research Group on Lymphoproliferative Disorders
María José Terol Casterá
- Research Group on Myeloid Neoplasms
María del Mar Tormo Díaz
- Research Group on Molecular Imaging and Metabolomics
Daniel Monleón Salvadó
- Research Group on Molecular Microbiology and Microbial Pathogenesis
David Navarro Ortega
- Medical Oncology Clinical Trials Unit: Phase I and experimental therapies
Andrés Cervantes Ruipérez

Emerging group

- Translational Research Group on Esophagogastric Cancer
Tania Carolina Fleitas Kanonnikoff

Number of publications

225

Average IF

10.15

Number of research projects

72

In December 2025 this area was renamed the **Cancer area** and the following new coordinator was appointed:



Coordinator:

Noelia Tarazona Llaveró



METABOLISM AND ORGAN DAMAGE AREA

Coordinator:

José Viña Ribes

Mission: advance understanding of the aetiology, pathophysiology, diagnosis mechanisms and treatment of various metabolic diseases, or those in which organ damage is directly linked with its trigger action.

22 research groups:

- Research Group on Genetics of Osteoporosis
Miguel Ángel García Pérez
- Research Group on Neurological Impairment
Carmina Montoliu Félix
- Research Group on Inflammation
María Jesús Sanz Ferrando
Laura Piqueras Ruiz
- Research Group on Psychiatry and Neurodegenerative Diseases
Juan Nacher Roselló
- Research Group on Respiratory Diseases
Jaime Signes-Costa Miñana
- Research Group on Tissue Biochemistry
Juan R. Viña Ribes
- Research Group on Ageing and Physical Activity
José Viña Ribes
- Research Group on Anaesthesiology and Reanimation
Rafael Badenes Quiles
- Research Group on Human Translational Genomics
Rubén D. Artero Allepuz
- Research Group on General and Digestive Surgery
Luis Sabater Ortí
- Research Group on Personal Autonomy, Dependence and Severe Mental Disorders (TMAP)
Rafael Tabarés Seisdedos
- Research Group on Cellular and Organic Physiopathology of Oxidative Stress
Federico Vicente Pallardó Calatayud
- Research Group on Healthy Ageing (Mini-Ageing)
Consuelo Borrás Blasco
- Research Group on Exercise, Nutrition and Healthy Lifestyle
María Carmen Gómez Cabrera
- Research Group on Genetics and Biomarkers of Rare Diseases
Carmen Espinós Armero

- Research Group on Nuclear Receptors in Cardiometabolic Pathology
Laura Piqueras Ruiz
- Mixed Unit on Neurological Impairment
Carmina Montoliu Félix
Carmen Espinós Armero
Jose Tomás Real Collado

Emerging groups

- Research group on Metabolic Diseases
Herminia González Navarro
- Research Group on Rare Respiratory Diseases (RRD)
Francisco Dasí Fernández

- Research Group on Epigenomics and Translational Epigenetics
José Luis García Giménez
- Research Group on Medical Chemistry for Drug Development
Nuria Cabedo Escrig
- Research Group on Neurobiology and Molecular Physiopathology in Rare Diseases – NeuroFisER
Pilar González Cabo

Number of publications

248

Average IF

7.63

Number of research projects

106

In December 2025, this area was split into the following two separate areas:

Rare Diseases area



Coordinator:

Federico Vicente Pallardó Calatayud



Coordinator:

Carmen Espinós Armero

Ageing, Inflammation and Chronic Diseases area



Coordinator:
María Jesús Sanz Ferrando



Coordinator:
Consuelo Borrás Blasco



REPRODUCTIVE MEDICINE
AREA

Coordinator:
Carlos Antonio Simón Vallés

Mission: advance understanding of human reproduction for translational application, improving the efficiency of assisted reproduction treatment and reducing adverse effects.

5 research groups:

- Research Group on Reproductive Medicine
Carlos Antonio Simón Vallés

- Mixed Unit of Reproductive Medicine
Carlos Antonio Simón Vallés

Emerging groups

- Research Group on Therapies Against Endometriosis and Endometrial Cancer
Raúl Gómez Gallego
- Research Group on Maternal–Fetal Communication
Felipe Vilella Mitjana
- Research Group on Molecular Diagnosis of Gynaecological Tumours
Aymara Mas Perucho

Number of publications

30

Average IF

5.71

Number of research projects

11

In December 2025, this area was renamed the **Women's Health area** and coordination has been updated as follows:



Coordinator:
Carlos Antonio Simón Vallés



Coordinator:
Felipe Vilella Mitjana



ASSOCIATED CLINICAL GROUPS AREA

9 research groups:

- Clinical Associated Group in Care.
INVESTENF-INCLIVA
Cintia Borja Herrero
- Clinical Associated Group in Urology
José Martínez Jabaloyas
- Clinical Associated Group in Digestive Medicine
Isabel Pascual Moreno
- Clinical Associated Group in Otorhinolaryngology
Jaime Marco Algarra
- Clinical Associated Group in Traumatology and Orthopaedics
Antonio Silvestre Muñoz
- Clinical Associated Group in Neurology
José Miguel Láinez Andrés
- Clinical Associated Group in Pharmacy
Manuel Alós Almiñana
- Clinical Associated Group in Nuclear Medicine
Rafael Díaz Expósito
- Clinical Associated Group in Insomnia and Circadian Rhythms
Manuel de Entrambasaguas Barreto

Number of publications

13

Average IF


3.45

Number of research projects

8

3. SCIENTIFIC OUTPUT

Indexed publications



The number of publications in 2025 was 686, with a cumulative impact factor of 5,127.4 translating into an average impact factor of 7.54.

Number of publications

686

Cumulative Impact Factor


5,127.4

Average Impact Factor


7.54

Quartile distribution

Approximately 98% of the papers published in indexed journals last year belong to the first and second quartiles of their corresponding thematic categories:




Doctoral theses defended



4. SCIENTIFIC ACTIVITY


Research projects

In 2025, 194 projects funded through public and private funds (175 national and 19 international) were active in competitive bidding, of which 50 new competitive projects were awarded (45 national and 5 international).




Clinical trials and other studies

As a result of its activity in 2025, INCLIVA managed a total of 178 studies (clinical trials and observational studies).



Evolution of clinical trial distributed by phase

During the period 2021-2025, INCLIVA prioritised Phase I and Phase II trials, fulfilling its objective of developing clinical research in its initial phases and thus contributing to translational research that moves scientific knowledge from bench to bedside.




Phase I oncology clinical trials

INCLIVA is the only hospital in Valencia and one of only a few in Spain performing Phase I cancer clinical trials, in which a substance or product is tested on humans for the first time.

In 2025, 465 ongoing clinical trials were conducted in the INCLIVA Oncology Department, 158 of which were related to treatment in the early stages of testing: 62 in Phase I (first in humans) and 96 in Phase II.

The following graph shows the number of Phase I oncology clinical trials during the last five years.




Research promotion initiatives

INCLIVA funded 18 grants in centres of excellence during 2025 to help researchers acquire new knowledge for clinical and research techniques.

In addition, six INCLIVA researchers undertook internships at external institutions (outgoing internships), while five researchers from other institutions completed internships at INCLIVA (incoming internships).

A total of 119 students enrolled in Vocational Training, Bachelor's or Master's degree programs were accepted for training internships in different research groups in INCLIVA during 2025.




5. KNOWLEDGE TRANSFER ACTIVITIES

As part of its organizational mission, INCLIVA Biomedical Research Institute is fully committed to transferring knowledge to both the National Health System and the industrial sector.

Knowledge transfer to the National Health System

Clinical guidelines and consensus documents are one of the best indicators of knowledge transfer from research to clinical practice. The number of guidelines with INCLIVA-affiliated author participation published in indexed journals in 2025 is shown below.



Innovation and knowledge transfer

INCLIVA's Innovation Unit supports INCLIVA professionals in developing translational research with greater societal impact, promotes innovation and collaboration with other research centres and industrial partners, and assesses the viability of innovative ideas at different stages to ensure that only the best ideas are launched on the market.



6. NETWORKS AND PLATFORMS

Cooperative research networks

The Carlos III Health Institute supports the creation of stable research network structures such as CIBER (Network of Centres for Biomedical Research). INCLIVA participates in this research structure through its associated groups.

Research Area	INCLIVA PI	Scientific Network	Reference
Cardiovascular	José Tomás Real Collado	<i>ciber</i> DEM	CB07/08/0018
	Empar Lurbe i Ferrer	<i>ciber</i> OBN	CB06/03/0039
	Vicent Bodí Peris	<i>ciber</i> CV	CB16/11/00486
	Juan Sanchis Forés	<i>ciber</i> CV	CB16/11/00420
Metabolism and Organ Damage	Federico V. Pallardó Calatayud	<i>ciber</i> ER	CB06/07/0073
	Ruben Artero Allepuz	<i>ciber</i> ER	CB23/07/00005
	Juan Nácher Roselló	<i>ciber</i> SAM	CB07/09/006
	Rafael Tabarés Seisdedos	<i>ciber</i> SAM	CB07/09/0021
	Mari Carmen Gómez Cabrera	<i>ciber</i> FES	CB16/10/00435
Oncology	Andrés Cervantes Ruipérez	<i>ciber</i> ONC	CB16/12/00473
	Rosa Noguera Salvá	<i>ciber</i> ONC	CB16/12/00484

National



International



7. HUMAN RESOURCES AT INCLIVA FROM A GENDER PERSPECTIVE

HR Excellence in Research


In 2019, INCLIVA obtained the HR Excellence in Research (HRS4R) quality seal, which recognizes the ability to attract talent, generate a favourable work environment, promote research and innovation, and enhance the careers of researchers within the European framework.



HR EXCELLENCE IN RESEARCH

Breakdown of research group staff


A total of 862 researchers belong to consolidated, emerging and associated research groups, with the following EURAXESS profile distribution:



Women and men working together at INCLIVA

As part of its commitment towards guaranteeing real equality between women and men, INCLIVA's Board of Trustees approved the III INCLIVA Equality Plan (2024–2028) following approval by the Equality Committee.


In 2025, a total of 319 employees joined INCLIVA, of whom 73% are women. The percentage of women hired has increased year on year for the last three years.



8. FINANCIAL RESOURCES


INCLIVA funding

INCLIVA received a total of €28,120,576 in funding in 2025.



Funding Sources in 2025


These funds come from competitive sources and grants, private funding sources and donations.



9. COMMUNICATION

Press office

During 2025, INCLIVA posted a total of 124 press releases on the website.



Social media users 2025

			
Facebook	X	LinkedIn	Instagram
7,692	6,403	23,543	3,716

Facebook: <https://www.facebook.com/INCLIVA>

X: https://twitter.com/incliva_iis

LinkedIn: <https://www.linkedin.com/company/incliva-instituto-de-investigaci3n-sanitaria>

Instagram: <https://www.instagram.com/iisincliva>

INCLIVA Website 2025



Website users	Website sessions	Website new sessions
143,321	261,738	137,213

Outreach 2025

News pieces on the INCLIVA website	News pieces on the radio	News pieces on TV
124	18	19

INCLIVA Biomedical Research Institute

Avda. Menéndez Pelayo, 4 accesorio

46010 Valencia / España

T. 34 96 197 35 17

F. 34 96 197 35 40

www.INCLIVA.es

INCLIVA@INCLIVA.es

Published by:

Fundación para la Investigación

del Hospital Clínico de la Comunidad Valenciana

INCLIVA Biomedical Research Institute

INCLIVA IVLC
Instituto de Investigación Sanitaria



INCLIVA | VLC

Biomedical Research Institute

